CME and CFTC Lock Horns Over On-Chain Perpetual Futures

In an unusual turn of events, the CME Group, the largest derivatives exchange operator in the US, has found itself at odds with its regulator, the Commodity Futures Trading Commission (CFTC), over the introduction of blockchain-based perpetual futures products. The CFTC's decision to allow the listing of these products, also known as perps, has been met with resistance from the CME, which claims that the regulator is misapplying the law by permitting the trading of contracts without expiration dates. The CME argues that perps are harmful to its traditional futures products and that the CFTC's sudden embrace of them did not consider the potential consequences. The lawsuit, which challenges the CFTC's approval of perps, has significant implications for the US approach to the rapidly growing market, with non-US perps volume reportedly reaching $60 trillion in 2023. The CFTC's move to allow perps has been seen as a departure from traditional futures contracts, which have expiration dates, and has sparked concerns about the potential risks and regulatory challenges associated with these products. As the CME and CFTC await federal court action, the outcome of this dispute is likely to have far-reaching consequences for the US derivatives market and the regulation of on-chain perpetual futures.